Patheon Acquires IRIX Pharmaceuticals
Patheon cites expanded API services with acquisition of IRIX Pharmaceuticals.
Patheon announced on March 4 that it has reached a definitive agreement to acquire Florence, SC-based IRIX Pharmaceuticals, which specializes in difficult-to-manufacture APIs for drugs from early and late development, through commercial launch. Patheon will purchase IRIX and expects to close the transaction in 60 days.
Patheon reports that with the acquisition, it secures additional API development and manufacturing services in the United States, including high-potency (SafeBridge Class IV-certified) and controlled substances (Schedule 1-4). IRIX has facilities for the optimization of chemical processes and scale up for commercial API manufacturing in Florence and Greenville, SC.
The combined companies will offer an array of process technologies, including biocatalysis, homogeneous catalysis, and microreactors and are positioned to address a range of supply chain issues for customers, according to a press statement.
Source: Patheon
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
Telix Enters Agreement with ImaginAb to Purchase Next-Gen Therapeutic Candidates
Published: January 13th 2025 | Updated: January 13th 2025The transaction adds a pipeline of early-stage drug candidates against high-value targets to Telix’s portfolio, along with other novel targets currently in the discovery stage.
